SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Novo Nordisk’s FREHEMGO Approved in EU for Haemophilia A

The European Commission granted marketing authorisation for FREHEMGO, with monthly, every-two-weeks or weekly dosing options.

NVO

Related stories